Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$12.50
+0.1%
$12.50
$8.29
$12.51
$799.18M1.391.46 million shs3.07 million shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$4.24
-11.1%
$4.77
$3.51
$16.95
$36.63M0.2485,579 shs250,371 shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$10.98
+1.2%
$8.23
$3.90
$14.67
$935.72M1.54785,612 shs467,182 shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$11.53
+0.5%
$10.33
$7.44
$11.82
$576.50M-0.02261,091 shs164,843 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.76
-4.2%
$4.49
$3.81
$6.37
$280.53M0.68600,477 shs454,540 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.00%0.00%0.00%0.00%+50.18%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
+4.84%+12.77%+8.66%+11.97%-66.30%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-2.25%+1.88%+12.67%+115.28%+7.85%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
+1.50%+1.41%+7.30%+32.91%+22.41%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
+4.85%+1.64%+10.20%+13.73%-16.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.6306 of 5 stars
1.00.00.04.50.01.70.6
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
4.0057 of 5 stars
3.50.00.04.62.92.50.6
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4.5719 of 5 stars
4.51.00.04.42.13.30.6
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
1.787 of 5 stars
3.30.00.00.02.02.50.6
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.694 of 5 stars
3.84.00.04.21.53.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.00
Hold$12.25-1.96% Downside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.00
Buy$37.40782.08% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
3.00
Buy$18.5769.14% Upside
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.67
Moderate Buy$16.6043.97% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50246.64% Upside

Current Analyst Ratings Breakdown

Latest KPTI, CDMO, ORIC, VNDA, and TBPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$27.00
7/8/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/27/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
6/23/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
6/17/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$24.00
5/29/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$139.91M5.71$0.15 per share80.92$3.02 per share4.14
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$142.13M0.26N/AN/A($22.10) per share-0.19
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.45 per shareN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$64.38M8.95N/AN/A$3.57 per share3.23
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$201.35M1.39N/AN/A$9.24 per share0.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$76.42M-$13.26N/AN/AN/A-43.99%N/A-35.95%8/5/2025 (Estimated)
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$56.42M-$1.18N/A32.94N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest KPTI, CDMO, ORIC, VNDA, and TBPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.46N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$3.72N/AN/AN/A$37.92 millionN/A
8/4/2025Q2 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.12N/AN/AN/A$16.04 millionN/A
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/12/2025Q1 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
5/5/2025Q1 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.51-$0.42+$0.09-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.58
1.30
0.92
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.33
1.28
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
12.00
12.00
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.77
4.77
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91
CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
32063.96 million62.01 millionOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.64 million8.40 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8085.22 million80.49 millionOptionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
11050.00 million46.55 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.69 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Avid Bioservices stock logo

Avid Bioservices NASDAQ:CDMO

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$4.24 -0.53 (-11.11%)
Closing price 04:00 PM Eastern
Extended Trading
$4.43 +0.19 (+4.48%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$10.98 +0.13 (+1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$10.98 -0.01 (-0.05%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$11.53 +0.06 (+0.52%)
Closing price 04:00 PM Eastern
Extended Trading
$11.53 0.00 (0.00%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.76 -0.21 (-4.23%)
Closing price 04:00 PM Eastern
Extended Trading
$4.85 +0.09 (+1.89%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.